Finerenone (FIN, BAY 94-8862) is a highly selective, orally active non-steroidal antagonist of mineralocorticoid receptor (MR) with an IC50 value of 18 nM. Finerenone has the potential to study cardio-renal diseases such as type 2 diabetes and chronic kidney disease.

 

Brand: BCM

 

Target: Mineralocorticoid Receptor:18 nM

 

Signaling Pathways: Endocrinology/Hormones

 

In Vitro: In vitro, Finerenone dose-dependently reduces aldosterone-induced smooth muscle cell (SMC) proliferation and prevents aldosteroneinduced endothelial cell (EC) apoptosis. Finerenone significantly reduces apoptosis of ECs and simultaneously attenuates SMC proliferation, resulting in accelerated endothelial healing and reduced neointima formation of the injured vessels.

 

Boiling Point: 554.7±50.0 °C(Predicted)

 

λmax: 255 nm

 

Solubility: Soluble in DMSO; soluble in Ethanol. Insoluble in Water.

 

GHS: GHS08, GHS06

 

Isomeric SMILES: CCOC1=NC=C(C2=C1[C@@H](C(=C(N2)C)C(=O)N)C3=C(C=C(C=C3)C#N)OC)C  

 

InChIKey: BTBHLEZXCOBLCY-QGZVFWFLSA-N  

 

InChI: InChI=1S/C21H22N4O3/c1-5-28-21-18-17(14-7-6-13(9-22)8-15(14)27-4)16(20(23)26)12(3)25-19(18)11(2)10-24-21/h6-8,10,17,25H,5H2,1-4H3,(H2,23,26)/t17-/m1/s1

 

Attribute
[Chem Name]	(4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
[Synonym]	Finerenone; BAY 94-8862; FIN
[CAS No.]	1050477-31-0
[MDL No.]	MFCD29047135
[Formula]	C21H22N4O3
[Molecular]	378.42
[Form]	White to off-white solid
[Storage]	Keep in dark place. Sealed in dry, 2-8°C

Goods Tag